Diede van den Ouden, a professional investor, has been nominated to become chief executive of TME Pharma NV, a clinical-stage company developing therapies for aggressive cancers. The candidate drugs target the tumour microenvironment and break tumour protection barriers against the immune system. Mr van den Ouden, a current shareholder, will enlarge his stake in the lead up to assuming the CEO position. He will replace Aram Mangasarian who will continue as an advisor to the company.
TME Pharma announced the appointment on 5 May 2025
Copyright 2025 Evernow Publishing Ltd